Antibody patents: Danger ahead for biologics
The evolution of antibody written description standards at the USPTO has put some drug portfolios at risk, say John Heithaus and Gerald Murphy of Birch, Stewart, Kolasch & Birch.
- Politics and IP: an unhealthy mix 13-12-2018
- Warner-Lambert: the plausibility test for sufficiency of disclosure 28-11-2018
- Mexico: new links between patents and pharmaceuticals 12-11-2018
- Generic competition: when one door closes, another opens 26-10-2018
- I-MAK: saving lives by curing the patent system 19-10-2018
Latest big pharma news
Gilead claims US government PrEP patents are invalid
20-05-2019
Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid.
